• Top page
  • Timetable
  • Per session
  • Per presentation
  • How to
  • Meeting Planner

演題詳細

Oral

アルツハイマー病、他の認知症、老化 1
Alzheimer's Disease, Other Dementia, Aging 1

開催日 2014/9/11
時間 14:00 - 15:00
会場 Room I(311+312)
Chairperson(s) 植木 孝俊 / Takatoshi Ueki (名古屋市立大学大学院医学研究科機能解剖学分野 / Department of Functional Anatomy, Nagoya City University Graduate School of Medical Sciences, Japan)
髙橋 淳 / Jun C. Takahashi (国立循環器病研究センター 脳神経外科 / Department of Neurosurgery, National Cerebral and Cardiovascular Center, Japan)

ノイロトロピン<00AE>の内服による脳内BDNFの増加と空間認知記憶能の改善
Increased BDNF levels and improved spatial learning in mice after the treatment with Neurotropin<00AE>

  • O1-I-3-1
  • 柳本 広二 / Hiroji Yanamoto:1 中城 有香子 / Yukako Nakajo:1,3 髙橋 淳 / Jun C Takahashi:4 
  • 1:国立循環器病センター研究所 / National Cerebral and Cardiovascular Research Center, Suita, Japan 2:大阪大学医学部 外科系循環制御 / Dept of Cardiovascular Science, Div of Surgical Med, Osaka Univ, Suita, Japan 3:洛和会音羽病院 実験研究室 / Rakuwakai Otowa Hosp, Research Laboratories, Japan 4:国立循環器病研究センター 脳神経外科 / Dept of Neurosurgery, National Cerebral and Cardiovascular Center, Japan 

There is an urgent need to develop a safe compound to enhance memory due to the growing number of people who are at risk of memory dysfunction due to Alzheimer's disease or vascular dementia. An extract from the inflamed cutaneous tissue of rabbits inoculated with vaccinia virus (ERV, Neurotropin®), utilized in the clinical treatment of chronic pain, was recently found to enhance the production of brain-derived neurotrophic factor (BDNF) in cultured neurons. As increased BDNF levels can enhance various brain functions, we examined the effect of daily oral ERV on spatial learning, and also on BDNF levels in the brain.
Following the daily administration of ERV at 0.27, 0.81 or 2.43 U/kg/day, or vehicle, for 21 days, the Morris water maze (MWM) test with modifications was performed using adult C57BL/6J mice. Each animal performed four trials per day (1 session), over five consecutive days without any prior or subsequent training. In each trial, the time needed to escape to the platform and the maximum velocity (Vmax) were analyzed. The BDNF levels in the brain were determined using ELISA.
Treatment with low, medium or high dose ERV improved the mean escape latencies in 2-5 sessions to 54% (P< 0.01), 31% (P< 0.001), and 41% (P< 0.001) respectively compared with controls (100%). Vmax significantly increased in the low dose group; 36.1 ± 3.2 cm/sec (P< 0.001), but did not differ in the medium or high dose groups (34.0 ± 3.8 cm/sec and 35.6 ± 3.8 cm/sec respectively) compared to the control: 32.8 ± 4.0cm/sec (mean ± SD). The BDNF levels in the brain were significantly elevated in the treated groups compared with controls (P< 0.001).
Daily oral treatment with ERV, especially at the medium dose: 0.81 U/kg/day, which is three times larger than that for humans, was found to increase BDNF levels in the brain and improve spatial learning.

Copyright © Neuroscience2014. All Right Reserved.